XTRA:MRK Earnings and Revenue History March 14th 2025 How Do Unusual Items Influence Profit? For anyone who wants to understand Merck KGaA's profit beyond the statutory numbers, i ...

While the company is in discussions to acquire SpringWorks, it did not elaborate on these talks in its earnings call.

One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. | One of Merck KGaA’s leading immunology ...

Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced ...

Merck KGaA on Thursday forecast currency-adjusted operating earnings growth of up to 8%, helped by demand for semiconductor ...

On February 10, 2025, the Group confirmed advanced discussions about a potential acquisition of SpringWorks Therapeutics ( SWTX ), Inc., USA. At the time of the preparation of the Consolidated ...

The board of Merck KGaA ( ETR:MRK ) has announced that it will pay a dividend of €2.20 per share on the 30th of ...

Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsFlorian Schraeder - Head of Investor ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...

Germany’s Merck KGaA (MRK: DE) returned to profitable growth in 2024 and delivered on its guidance for the year.

Germany’s Merck KGaA expects earnings and sales growth this year after reporting a rise in annual earnings on temporarily reduced research and development expenses in its healthcare segment and ...